{
  "name": "Vertex Pharmaceuticals",
  "slug": "vertex-pharmaceuticals",
  "ticker": "VRTX",
  "fetched_at": "2025-08-11T12:25:10.629498+00:00",
  "news": [
    {
      "title": "Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQX254NDI2LU9zdm12TmpoWTNvNjlUaXlFQzlKT0FMSnlaUkZ0c2duT2NlTS1iQ0dkSXUxY2pMYTNnTGtqQlA4Z3JPOW8xeHNFWW9kZjFya3NldTJINmNFWTRYUE1xQmgtRDRrSjhieDFnNHVQRkFTVlZoUUN3N25ZeE14VTJhcGgzTjI0?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQX254NDI2LU9zdm12TmpoWTNvNjlUaXlFQzlKT0FMSnlaUkZ0c2duT2NlTS1iQ0dkSXUxY2pMYTNnTGtqQlA4Z3JPOW8xeHNFWW9kZjFya3NldTJINmNFWTRYUE1xQmgtRDRrSjhieDFnNHVQRkFTVlZoUUN3N25ZeE14VTJhcGgzTjI0?oc=5\" target=\"_blank\">Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-08-05T19:50:50+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip - The Motley Fool",
      "link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNRURkTWw0Y1VEdmRxSGQwYXEwUzlZbTd6Q1ZLaVVmMkpaVmU1eG9weWpsRlZ5WDJpVzBvaU9kRWpkRHd2blVJczVxNktTdkc3bFRvTmFkeURoc05NY2QtQ2xzYVQ5cWJad3kwSGxHQTR1MHh2dUZUUzZsc25XdWhWaUpDeWVVOXg2MmVRZU55RTBMVU40MzAybw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimAFBVV95cUxNRURkTWw0Y1VEdmRxSGQwYXEwUzlZbTd6Q1ZLaVVmMkpaVmU1eG9weWpsRlZ5WDJpVzBvaU9kRWpkRHd2blVJczVxNktTdkc3bFRvTmFkeURoc05NY2QtQ2xzYVQ5cWJad3kwSGxHQTR1MHh2dUZUUzZsc25XdWhWaUpDeWVVOXg2MmVRZU55RTBMVU40MzAybw?oc=5\" target=\"_blank\">7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Motley Fool</font>",
      "published": "2025-08-06T08:42:00+00:00",
      "source": "The Motley Fool"
    },
    {
      "title": "Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat - Investor's Business Daily",
      "link": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPMGFNTjBhUnB5R2tQVzJIZWN2aHlJZ09Rd0VWaThnSWlOd2NKODBHWXo1ZjVVY1o2bzk0aUQtTG5MN0hMNmo4akdyT0tZZ1IwN2ZsQkZSSnJ5cWtMTmRWNGNOSVEydjc4QnZWTmdxR3ZCblhTQ0VEUXFZazdTMndnWmhuU0s2YmdEVHVxNXRFNFRnMi1ROW83MUF3bw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimwFBVV95cUxPMGFNTjBhUnB5R2tQVzJIZWN2aHlJZ09Rd0VWaThnSWlOd2NKODBHWXo1ZjVVY1o2bzk0aUQtTG5MN0hMNmo4akdyT0tZZ1IwN2ZsQkZSSnJ5cWtMTmRWNGNOSVEydjc4QnZWTmdxR3ZCblhTQ0VEUXFZazdTMndnWmhuU0s2YmdEVHVxNXRFNFRnMi1ROW83MUF3bw?oc=5\" target=\"_blank\">Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investor's Business Daily</font>",
      "published": "2025-08-05T20:20:00+00:00",
      "source": "Investor's Business Daily"
    },
    {
      "title": "Advocates urge South Africa to reopen antitrust probe into Vertex Pharmaceuticals - statnews.com",
      "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNa29lMEJqdk1mYm4ycTltcXBaTUprcW5vTFJNRjZzN092anY2Z3AteTVsbTh6MTM1Q3dTT2R6NEd3elVJRnRMZFYyZlNFdGpxeHZwdUxUNTZveWtlS2RVUXIyZDJkZ2p4ZjB4eTFUZ01qMTBuT1dDVHBMVXZQRnRldWdmTFVvYVFqLWNkclU3SzAyYW5JMkZOQXNOcnN1LU9VUTBLNHkxZFkyMXB4TEEzQnM4c0tuanJqMjFPeGRRSXE?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNa29lMEJqdk1mYm4ycTltcXBaTUprcW5vTFJNRjZzN092anY2Z3AteTVsbTh6MTM1Q3dTT2R6NEd3elVJRnRMZFYyZlNFdGpxeHZwdUxUNTZveWtlS2RVUXIyZDJkZ2p4ZjB4eTFUZ01qMTBuT1dDVHBMVXZQRnRldWdmTFVvYVFqLWNkclU3SzAyYW5JMkZOQXNOcnN1LU9VUTBLNHkxZFkyMXB4TEEzQnM4c0tuanJqMjFPeGRRSXE?oc=5\" target=\"_blank\">Advocates urge South Africa to reopen antitrust probe into Vertex Pharmaceuticals</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">statnews.com</font>",
      "published": "2025-08-08T16:13:27+00:00",
      "source": "statnews.com"
    },
    {
      "title": "Vertex drops aspiring Journavx follower in acute pain after phase 2 failure - Fierce Biotech",
      "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQNE9GQlVQWG5kQnBnZlFPUS1oTklTTnBaREtpMWFxbDJaakt5bExadmVJLUREME5Lem4yRDdKLTV0Qlo1bUtycUZ1anV6emNPb25XaXRoSVJXRHZodXZVZzl1MmhHNkdUcE8tc2l3eGprcFN0Z3RLYVhDZGpBTURLNGZzUGFOeVlTZy1XQXY1TUdIakxmM0ZPQmMwMTE5LUxRVllKc1JVbGI0amNCODBr?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMirwFBVV95cUxQNE9GQlVQWG5kQnBnZlFPUS1oTklTTnBaREtpMWFxbDJaakt5bExadmVJLUREME5Lem4yRDdKLTV0Qlo1bUtycUZ1anV6emNPb25XaXRoSVJXRHZodXZVZzl1MmhHNkdUcE8tc2l3eGprcFN0Z3RLYVhDZGpBTURLNGZzUGFOeVlTZy1XQXY1TUdIakxmM0ZPQmMwMTE5LUxRVllKc1JVbGI0amNCODBr?oc=5\" target=\"_blank\">Vertex drops aspiring Journavx follower in acute pain after phase 2 failure</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>",
      "published": "2025-08-04T21:34:36+00:00",
      "source": "Fierce Biotech"
    },
    {
      "title": "Vertex's trial failure, scrapped study cloud pain drug push; shares slump - Reuters",
      "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQOEk3LXI4VjBsT0J1aDNCc3BvU3ZZYTgzRlBGOEFuejM3QzFST3lZT3hMUGtNVFFDazVoblY1bUM3bHo2Q1BpOXdCMGx2b0ZvS19qNFl1M3AzUG9zQ1haaWU2Wnk4Y1ZzaEVRRC14RExYMWh3MGM2OWRFekF6NW1yNjhzeXNySFVqc1hhdEdlMjI3ZG4tcnVIdWNGeVI3eU9PSzA5eVdvQVBRNVJETFI5SGtRZDhPWkhxVFllcmp3U3NsZVRfRDRxdGNLbExUS29JcDhkMlV0YTBSQQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQOEk3LXI4VjBsT0J1aDNCc3BvU3ZZYTgzRlBGOEFuejM3QzFST3lZT3hMUGtNVFFDazVoblY1bUM3bHo2Q1BpOXdCMGx2b0ZvS19qNFl1M3AzUG9zQ1haaWU2Wnk4Y1ZzaEVRRC14RExYMWh3MGM2OWRFekF6NW1yNjhzeXNySFVqc1hhdEdlMjI3ZG4tcnVIdWNGeVI3eU9PSzA5eVdvQVBRNVJETFI5SGtRZDhPWkhxVFllcmp3U3NsZVRfRDRxdGNLbExUS29JcDhkMlV0YTBSQQ?oc=5\" target=\"_blank\">Vertex's trial failure, scrapped study cloud pain drug push; shares slump</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Reuters</font>",
      "published": "2025-08-04T23:38:51+00:00",
      "source": "Reuters"
    },
    {
      "title": "The Escalator: Geron, Vertex Pharmaceuticals, Butler/Till and more - Medical Marketing and Media",
      "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQMENsbFVVWWpEbGVLMXQwOXdvOGFxQnJQZ2poZW01ME56ZFdMVldIWEpjRllSTGw1NGxCUko1V3ZwbWlGTlNUVDBmNE5ON0hYeVhRSUlFd0t2X0pUMXRDMVJrSFNTV1BaRWNHZHVKanZPR1JzWGRJUU8tN1lVcENjNUpsNFd1NS1xRzNfb1hYUm1rVVplendwT3ZJc3I?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMinAFBVV95cUxQMENsbFVVWWpEbGVLMXQwOXdvOGFxQnJQZ2poZW01ME56ZFdMVldIWEpjRllSTGw1NGxCUko1V3ZwbWlGTlNUVDBmNE5ON0hYeVhRSUlFd0t2X0pUMXRDMVJrSFNTV1BaRWNHZHVKanZPR1JzWGRJUU8tN1lVcENjNUpsNFd1NS1xRzNfb1hYUm1rVVplendwT3ZJc3I?oc=5\" target=\"_blank\">The Escalator: Geron, Vertex Pharmaceuticals, Butler/Till and more</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Medical Marketing and Media</font>",
      "published": "2025-08-06T20:07:09+00:00",
      "source": "Medical Marketing and Media"
    },
    {
      "title": "Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug - Investopedia",
      "link": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPSm1iMzM5VjEteHhaVHNhempsaUUwVmJzc3NmSlpVRnhkeWRVWmhlR2d3b0RZMzhZdXdzT28wU0FtbUczSXNoUDZCMnJPZGk5ZERFYVh4Z2RmZ3ZzOUM3QTdwc0tQdDFWR092VjIwSllxNWdpTE1OUTRxcVVKMzR4aURwZmVkdENiWHBsVi1PcGJ2cy1ab0NpUHVoN2QwdFYzYldTMnNLc2lrUEV3bm1MSlVaTG0?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMitAFBVV95cUxPSm1iMzM5VjEteHhaVHNhempsaUUwVmJzc3NmSlpVRnhkeWRVWmhlR2d3b0RZMzhZdXdzT28wU0FtbUczSXNoUDZCMnJPZGk5ZERFYVh4Z2RmZ3ZzOUM3QTdwc0tQdDFWR092VjIwSllxNWdpTE1OUTRxcVVKMzR4aURwZmVkdENiWHBsVi1PcGJ2cy1ab0NpUHVoN2QwdFYzYldTMnNLc2lrUEV3bm1MSlVaTG0?oc=5\" target=\"_blank\">Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investopedia</font>",
      "published": "2025-08-05T13:52:29+00:00",
      "source": "Investopedia"
    }
  ],
  "product_launches": [
    {
      "title": "Vertex tops estimates on cystic fibrosis treatment strength, new products - Reuters",
      "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQV1RfcWFhZlB4RnlGTUNfYlJTOEFKaHREZHlEeV9GVHpnaW1zRDliVlMtX3dWdjZkS2RNRWhZaXc0NmdVcW10bVhmQV9NNlh3b3IwckhEME9rTFlIci1hRDF4RlFzRWprOWFTdjlVV1d4dVpIaVFGWXBiWF9tbnJmcFEydUxiNDF1TVJfLTI4QmtvcnIwWVhYd3hNTno2aFhpZF9WNFZjX3lJLVVsNjZfcWZOVTVzU2lXYzV1cmw0bDRpTUFiWjJLUElvRk15d1RKLWJnQy10MmU?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQV1RfcWFhZlB4RnlGTUNfYlJTOEFKaHREZHlEeV9GVHpnaW1zRDliVlMtX3dWdjZkS2RNRWhZaXc0NmdVcW10bVhmQV9NNlh3b3IwckhEME9rTFlIci1hRDF4RlFzRWprOWFTdjlVV1d4dVpIaVFGWXBiWF9tbnJmcFEydUxiNDF1TVJfLTI4QmtvcnIwWVhYd3hNTno2aFhpZF9WNFZjX3lJLVVsNjZfcWZOVTVzU2lXYzV1cmw0bDRpTUFiWjJLUElvRk15d1RKLWJnQy10MmU?oc=5\" target=\"_blank\">Vertex tops estimates on cystic fibrosis treatment strength, new products</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Reuters</font>",
      "published": "2025-08-04T21:40:32+00:00",
      "source": "Reuters"
    },
    {
      "title": "Vertex Pharmaceuticals: Strong Growth and Strategic Advances - TipRanks",
      "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxORGtLZUtKRE5VMFp1WV9YQ3VFU2QySUg0c3pYQjIxNXFDTzlldmw3SGF5emctdmxCWVllTTgyUThPUU1xTkNDRUx2a1ZUTWxUUzg0VVMxd0YzVXJTelFPYk0xdDZHa0pobUJPcVRnenlldm05d2NoTzlPc21vamI5QTVaRTk5UVRDaGRpYm1BbjZPM1h3bWtrMkxueUg0azRQdmwzRi1UMHVsWldERzBQQw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisAFBVV95cUxORGtLZUtKRE5VMFp1WV9YQ3VFU2QySUg0c3pYQjIxNXFDTzlldmw3SGF5emctdmxCWVllTTgyUThPUU1xTkNDRUx2a1ZUTWxUUzg0VVMxd0YzVXJTelFPYk0xdDZHa0pobUJPcVRnenlldm05d2NoTzlPc21vamI5QTVaRTk5UVRDaGRpYm1BbjZPM1h3bWtrMkxueUg0azRQdmwzRi1UMHVsWldERzBQQw?oc=5\" target=\"_blank\">Vertex Pharmaceuticals: Strong Growth and Strategic Advances</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>",
      "published": "2025-08-06T00:26:42+00:00",
      "source": "TipRanks"
    },
    {
      "title": "Vertex Pharmaceuticals: A Masterclass in Diversified Innovation and Financial Discipline - AInvest",
      "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOZHpaSFhxbWZ5TkFaSlY2eDUwTW9fd2QwelRqS2tYQy1kclVuVmpjNHp2MmZCOGJ6UkZ2OVFicXlYcEhDSU9RZm9GWGJYWC0tTlFsc3NBdjFvaVA0V1lTX3h5Y29McmpaUGY1bDJma004M3FBTGc5OXh4b1p5MGNHWEhlUU1nNWI4ei1HTjBsRjBVbnJsZGtXdU5fNlpJS0QzaHc5VFZOSzZsbTF6SWxxRGZkaw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiswFBVV95cUxOZHpaSFhxbWZ5TkFaSlY2eDUwTW9fd2QwelRqS2tYQy1kclVuVmpjNHp2MmZCOGJ6UkZ2OVFicXlYcEhDSU9RZm9GWGJYWC0tTlFsc3NBdjFvaVA0V1lTX3h5Y29McmpaUGY1bDJma004M3FBTGc5OXh4b1p5MGNHWEhlUU1nNWI4ei1HTjBsRjBVbnJsZGtXdU5fNlpJS0QzaHc5VFZOSzZsbTF6SWxxRGZkaw?oc=5\" target=\"_blank\">Vertex Pharmaceuticals: A Masterclass in Diversified Innovation and Financial Discipline</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>",
      "published": "2025-08-05T02:56:10+00:00",
      "source": "AInvest"
    },
    {
      "title": "Vertex Reports Second Quarter 2025 Financial Results - Business Wire",
      "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQMWJFb2Noa0FVRVkzbmRWczF1SW5EcTk5RDNFUUxILUdsYW9veGlEbnV1SkY2S0p2WFRBYV9JVFFEUkUtc3BFN1hhRk55TklJcFlOWnlIU012RlhqVnl3aU5oUHpOZ3B6TXNReExoMEl5QWRRRHBVOE9aUUJudVZzLV9qTUhOQ1hZTHlnNTNuN2ZPb2tCV056enlVR1dWVl9Lb2dldEFxcG92UklZeEE?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMirgFBVV95cUxQMWJFb2Noa0FVRVkzbmRWczF1SW5EcTk5RDNFUUxILUdsYW9veGlEbnV1SkY2S0p2WFRBYV9JVFFEUkUtc3BFN1hhRk55TklJcFlOWnlIU012RlhqVnl3aU5oUHpOZ3B6TXNReExoMEl5QWRRRHBVOE9aUUJudVZzLV9qTUhOQ1hZTHlnNTNuN2ZPb2tCV056enlVR1dWVl9Lb2dldEFxcG92UklZeEE?oc=5\" target=\"_blank\">Vertex Reports Second Quarter 2025 Financial Results</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Business Wire</font>",
      "published": "2025-08-04T20:01:00+00:00",
      "source": "Business Wire"
    },
    {
      "title": "(suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain - Vertex Pharmaceuticals Newsroom",
      "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQNGhZSnljSUNJSGJ4SzNPVXdNeXNncWRyT1dUWVY2VDVxWDFhamJGQUtSWlhJLVVJMmhSQjROckJNemJGZVlkY3ZmR0ZmYXBiX1J1ZHExdk1ZOW1wTWp5T1ZWa283c2RkYjdkUlgwMEtNejlNb3NJbVZJZlpyVmNweWptQ3dWeDAtV0NfVEJXNG5RU1pTZFRUY01hOEd0SXdwMXFTdEpGTnJTMklMX2NRUnBwUGhndjcyWUJzc0pn?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivgFBVV95cUxQNGhZSnljSUNJSGJ4SzNPVXdNeXNncWRyT1dUWVY2VDVxWDFhamJGQUtSWlhJLVVJMmhSQjROckJNemJGZVlkY3ZmR0ZmYXBiX1J1ZHExdk1ZOW1wTWp5T1ZWa283c2RkYjdkUlgwMEtNejlNb3NJbVZJZlpyVmNweWptQ3dWeDAtV0NfVEJXNG5RU1pTZFRUY01hOEd0SXdwMXFTdEpGTnJTMklMX2NRUnBwUGhndjcyWUJzc0pn?oc=5\" target=\"_blank\">(suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Vertex Pharmaceuticals Newsroom</font>",
      "published": "2025-01-30T08:00:00+00:00",
      "source": "Vertex Pharmaceuticals Newsroom"
    }
  ],
  "stock": {
    "ticker": "VRTX",
    "currency": "USD",
    "latest": {
      "date": "2025-08-08",
      "close": 366.5400085449219
    },
    "history": [
      {
        "date": "2025-07-31",
        "close": 456.8699951171875
      },
      {
        "date": "2025-08-01",
        "close": 462.1300048828125
      },
      {
        "date": "2025-08-04",
        "close": 472.2699890136719
      },
      {
        "date": "2025-08-05",
        "close": 374.9800109863281
      },
      {
        "date": "2025-08-06",
        "close": 385.6499938964844
      },
      {
        "date": "2025-08-07",
        "close": 375.6300048828125
      },
      {
        "date": "2025-08-08",
        "close": 366.5400085449219
      }
    ],
    "name": "Vertex Pharmaceuticals Incorpor"
  }
}